<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836589</url>
  </required_header>
  <id_info>
    <org_study_id>GALAXY</org_study_id>
    <nct_id>NCT00836589</nct_id>
  </id_info>
  <brief_title>Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)</brief_title>
  <acronym>GALAXY</acronym>
  <official_title>GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to confirm the long-term safety and reliability of the Linox
      Lead System as used with BIOTRONIK ICDs. The GALAXY registry will provide data to fully
      characterize ICD lead failures, from implant through 5 years, including those failures
      contributing to patients losing pacing or defibrillation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, prospective, non-randomized, 5-year data collection registry.
      Eligible patients must have been successfully implanted with a Linox Lead System connected to
      a BIOTRONIK ICD and consented and enrolled between 1-45 days following implant. This study is
      designed to be a post-implant (office-based) registry, and patients are meant to be seen
      according to each institution's standard of care, but not to exceed a follow-up time frame of
      every 6 months. At least 2000 patients will be enrolled in this registry, and each patient
      will be followed for five years post-implant.

      Safety will be evaluated based on the analysis of the overall incidence of lead-related
      adverse events that require additional invasive intervention to resolve. In addition, each
      individual adverse event will be separately investigated. Lead parameters for sensing, pacing
      thresholds, and impedance will also be evaluated. An independent Clinical Events Committee
      will review and adjudicate all adverse events that occur during the study according to the
      protocol definitions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Are Free of Complications Related to the Linox ICD Lead</measure>
    <time_frame>5 years</time_frame>
    <description>The overall incidence of complications (serious adverse events that require additional invasive intervention to resolve or specific non-invasive actions) related to the Linox ICD leads implanted with a market-released BIOTRONIK ICD device was evaluated. This was evaluated as a serious adverse event free-rate (SAEFR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Experienced Primary Outcome 1 Complication(s) Per Individual Complication Type</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of the individual types of serious adverse events (SAEs) contributing to primary outcome 1 and their associated SAE category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experienced Serious Adverse Event(s) Excluded From Primary Outcome 1 (ICD, Device, and Implant Procedure Related) Through 5 Years Post-Implant.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experienced Serious Adverse Event(s) Excluded From Primary Outcome 1 (RA Lead Related) Through 5 Years Post-Implant.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing Threshold Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</measure>
    <time_frame>5 years</time_frame>
    <description>Pacing thresholds performed at 0.5 ms pulse-width were requested. Threshold data reported below was collected at 0.5 ms pulse-width. The mean pacing threshold is calculated as a mean across all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensing Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</measure>
    <time_frame>5 years</time_frame>
    <description>The mean sensing measurement is calculated as a mean across all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing Impedance Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</measure>
    <time_frame>5 years</time_frame>
    <description>The mean pacing impedance measurement is calculated as a mean across all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Electrical Parameters (Pacing Threshold) of Each Linox Lead System Model.</measure>
    <time_frame>5 years</time_frame>
    <description>Pacing thresholds performed at 0.5 ms pulse-width were requested. Threshold data reported below was collected at 0.5 ms pulse-width. The mean pacing threshold of each Linox Lead System model was calculated as a mean across all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Electrical Parameters (Sensing) of Each Linox Lead System Model.</measure>
    <time_frame>5 years</time_frame>
    <description>The mean sensing measurements of each Linox Lead System model were calculated as a mean across all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Electrical Parameters (Pacing Impedance) of Each Linox Lead System Model.</measure>
    <time_frame>5 years</time_frame>
    <description>The mean pacing impedance of each Linox Lead System model was calculated as a mean across all study visits.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1997</enrollment>
  <condition>Patients Indicated for an ICD</condition>
  <arm_group>
    <arm_group_label>Data Collection Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD Therapy - ICD Lead Registry</intervention_name>
    <description>Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
    <arm_group_label>Data Collection Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be obtained from the investigators' general patient population according to
        the inclusion and exclusion criteria described below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully implanted Linox Lead System connected to a BIOTRONIK ICD, from 1-45 days
             prior to enrollment

          -  Able to understand the nature of the registry and provide informed consent

          -  Available for follow-up visits on a regular basis at the investigational site

          -  Age greater than or equal to 18 years

        Exclusion Criteria:

          -  Enrolled in any IDE clinical study

          -  Planned cardiac surgical procedures or investigational measures within the next 6
             months

          -  Expected to receive a heart transplant within 1 year

          -  Life expectancy less than 1 year

          -  Presence of another life-threatening, underlying illness separate from their cardiac
             disorder

          -  Pregnancy

          -  Inability to provide date of implant, devices implanted, age, gender, and whether the
             patient experienced any protocol-defined adverse events since implant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Albertville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gadsden</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawthorne</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alton</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centralia</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crystal City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Massillon</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chinchilla</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>December 18, 2017</results_first_submitted>
  <results_first_submitted_qc>September 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long-term safety and reliability of ICD leads</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Data Collection Group</title>
          <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1997"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="731"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1266"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject or Physician</title>
              <participants_list>
                <participants group_id="P1" count="591"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Data Collection Group</title>
          <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1997"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age at Enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="537"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Amerian Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>in</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194.2" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Are Free of Complications Related to the Linox ICD Lead</title>
        <description>The overall incidence of complications (serious adverse events that require additional invasive intervention to resolve or specific non-invasive actions) related to the Linox ICD leads implanted with a market-released BIOTRONIK ICD device was evaluated. This was evaluated as a serious adverse event free-rate (SAEFR).</description>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>Data Collection Group</title>
            <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Are Free of Complications Related to the Linox ICD Lead</title>
          <description>The overall incidence of complications (serious adverse events that require additional invasive intervention to resolve or specific non-invasive actions) related to the Linox ICD leads implanted with a market-released BIOTRONIK ICD device was evaluated. This was evaluated as a serious adverse event free-rate (SAEFR).</description>
          <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="88.6" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Estimated SAEFR at 5 years is 92.5% with a 5% non-inferiority margin (87.5%).
Type I error (alpha) is 0.05 (one-sided for non-inferiority).
Statistical power is 80%.</non_inferiority_desc>
            <p_value>0.0020</p_value>
            <method>Binomial Proportion</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Experienced Primary Outcome 1 Complication(s) Per Individual Complication Type</title>
        <description>Evaluation of the individual types of serious adverse events (SAEs) contributing to primary outcome 1 and their associated SAE category.</description>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>Data Collection Group</title>
            <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experienced Primary Outcome 1 Complication(s) Per Individual Complication Type</title>
          <description>Evaluation of the individual types of serious adverse events (SAEs) contributing to primary outcome 1 and their associated SAE category.</description>
          <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low lead impedance, potential insulation breach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High lead impedance, potential conductor fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lead noise or oversensing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lead dislodgement (&gt;180 days post-implant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lead undersensing or loss of sensing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inability to defibrillate or pace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No slack in lead due to probable dislodgement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noise consistent with probable fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension pneumothorax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experienced Serious Adverse Event(s) Excluded From Primary Outcome 1 (ICD, Device, and Implant Procedure Related) Through 5 Years Post-Implant.</title>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a secondary endpoint adverse event (ICD lead, device, implant procedure, or other related).</population>
        <group_list>
          <group group_id="O1">
            <title>Data Collection Group</title>
            <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experienced Serious Adverse Event(s) Excluded From Primary Outcome 1 (ICD, Device, and Implant Procedure Related) Through 5 Years Post-Implant.</title>
          <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a secondary endpoint adverse event (ICD lead, device, implant procedure, or other related).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="830"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total related to the ICD lead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total device related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total implant procedure related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total other AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experienced Serious Adverse Event(s) Excluded From Primary Outcome 1 (RA Lead Related) Through 5 Years Post-Implant.</title>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and had an RA lead implanted for any duration and/or who experienced a secondary endpoint adverse event (RA lead related).</population>
        <group_list>
          <group group_id="O1">
            <title>Data Collection Group</title>
            <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experienced Serious Adverse Event(s) Excluded From Primary Outcome 1 (RA Lead Related) Through 5 Years Post-Implant.</title>
          <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and had an RA lead implanted for any duration and/or who experienced a secondary endpoint adverse event (RA lead related).</population>
          <units>subjects with adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pacing Threshold Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</title>
        <description>Pacing thresholds performed at 0.5 ms pulse-width were requested. Threshold data reported below was collected at 0.5 ms pulse-width. The mean pacing threshold is calculated as a mean across all study visits.</description>
        <time_frame>5 years</time_frame>
        <population>17 subjects were excluded due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linox Lead System</title>
            <description>Linox leads including S, SD, T, and TD models, Linox smart leads including smart S, smart SD, and smart TD models.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Threshold Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</title>
          <description>Pacing thresholds performed at 0.5 ms pulse-width were requested. Threshold data reported below was collected at 0.5 ms pulse-width. The mean pacing threshold is calculated as a mean across all study visits.</description>
          <population>17 subjects were excluded due to incomplete data.</population>
          <units>Volts (V)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1980"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensing Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</title>
        <description>The mean sensing measurement is calculated as a mean across all study visits.</description>
        <time_frame>5 years</time_frame>
        <population>17 subjects were excluded due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linox Lead System</title>
            <description>Linox leads including S, SD, T, and TD models, Linox smart leads including smart S, smart SD, and smart TD models.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensing Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</title>
          <description>The mean sensing measurement is calculated as a mean across all study visits.</description>
          <population>17 subjects were excluded due to incomplete data.</population>
          <units>millivolts (mV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1980"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.77" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pacing Impedance Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</title>
        <description>The mean pacing impedance measurement is calculated as a mean across all study visits.</description>
        <time_frame>5 years</time_frame>
        <population>17 subjects were excluded due to incomplete data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linox Lead System</title>
            <description>Linox leads including S, SD, T, and TD models, Linox smart leads including smart S, smart SD, and smart TD models.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Impedance Measurements for the Linox Lead System at Scheduled GALAXY Registry Follow-ups Through 5 Years Post-implant.</title>
          <description>The mean pacing impedance measurement is calculated as a mean across all study visits.</description>
          <population>17 subjects were excluded due to incomplete data.</population>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1980"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.9" spread="136.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Electrical Parameters (Pacing Threshold) of Each Linox Lead System Model.</title>
        <description>Pacing thresholds performed at 0.5 ms pulse-width were requested. Threshold data reported below was collected at 0.5 ms pulse-width. The mean pacing threshold of each Linox Lead System model was calculated as a mean across all study visits.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linox S</title>
          </group>
          <group group_id="O2">
            <title>Linox SD</title>
          </group>
          <group group_id="O3">
            <title>Linox T</title>
          </group>
          <group group_id="O4">
            <title>Linox TD</title>
          </group>
          <group group_id="O5">
            <title>Linox Smart S</title>
          </group>
          <group group_id="O6">
            <title>Linox Smart SD</title>
          </group>
          <group group_id="O7">
            <title>Linox Smart TD</title>
          </group>
        </group_list>
        <measure>
          <title>Individual Electrical Parameters (Pacing Threshold) of Each Linox Lead System Model.</title>
          <description>Pacing thresholds performed at 0.5 ms pulse-width were requested. Threshold data reported below was collected at 0.5 ms pulse-width. The mean pacing threshold of each Linox Lead System model was calculated as a mean across all study visits.</description>
          <units>Volts (V)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="1352"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.31"/>
                    <measurement group_id="O2" value="0.64" spread="0.33"/>
                    <measurement group_id="O3" value="0.50" spread="0.00"/>
                    <measurement group_id="O4" value="0.76" spread="0.62"/>
                    <measurement group_id="O5" value="0.59" spread="0.22"/>
                    <measurement group_id="O6" value="0.66" spread="0.46"/>
                    <measurement group_id="O7" value="0.67" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Electrical Parameters (Sensing) of Each Linox Lead System Model.</title>
        <description>The mean sensing measurements of each Linox Lead System model were calculated as a mean across all study visits.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linox S</title>
          </group>
          <group group_id="O2">
            <title>Linox SD</title>
          </group>
          <group group_id="O3">
            <title>Linox T</title>
          </group>
          <group group_id="O4">
            <title>Linox TD</title>
          </group>
          <group group_id="O5">
            <title>Linox Smart S</title>
          </group>
          <group group_id="O6">
            <title>Linox Smart SD</title>
          </group>
          <group group_id="O7">
            <title>Linox Smart TD</title>
          </group>
        </group_list>
        <measure>
          <title>Individual Electrical Parameters (Sensing) of Each Linox Lead System Model.</title>
          <description>The mean sensing measurements of each Linox Lead System model were calculated as a mean across all study visits.</description>
          <units>millivolts (mV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="1352"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="5.69"/>
                    <measurement group_id="O2" value="12.71" spread="5.41"/>
                    <measurement group_id="O3" value="5.63" spread="0.81"/>
                    <measurement group_id="O4" value="10.96" spread="4.06"/>
                    <measurement group_id="O5" value="13.12" spread="5.14"/>
                    <measurement group_id="O6" value="12.25" spread="4.93"/>
                    <measurement group_id="O7" value="10.25" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Electrical Parameters (Pacing Impedance) of Each Linox Lead System Model.</title>
        <description>The mean pacing impedance of each Linox Lead System model was calculated as a mean across all study visits.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linox S</title>
          </group>
          <group group_id="O2">
            <title>Linox SD</title>
          </group>
          <group group_id="O3">
            <title>Linox T</title>
          </group>
          <group group_id="O4">
            <title>Linox TD</title>
          </group>
          <group group_id="O5">
            <title>Linox Smart S</title>
          </group>
          <group group_id="O6">
            <title>Linox Smart SD</title>
          </group>
          <group group_id="O7">
            <title>Linox Smart TD</title>
          </group>
        </group_list>
        <measure>
          <title>Individual Electrical Parameters (Pacing Impedance) of Each Linox Lead System Model.</title>
          <description>The mean pacing impedance of each Linox Lead System model was calculated as a mean across all study visits.</description>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="1352"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.9" spread="105.3"/>
                    <measurement group_id="O2" value="541.8" spread="120.5"/>
                    <measurement group_id="O3" value="812.0" spread="202.5"/>
                    <measurement group_id="O4" value="784.8" spread="306.2"/>
                    <measurement group_id="O5" value="541.5" spread="106.5"/>
                    <measurement group_id="O6" value="546.0" spread="99.2"/>
                    <measurement group_id="O7" value="734.4" spread="253.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Implant to Study Exit (up to 5 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Data Collection Group</title>
          <description>ICD Therapy - ICD Lead Registry: Collecting long-term safety and efficacy data on a family of market-released ICD leads.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="429" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ICD lead dislodgement (occuring &lt;= 180 days post-implant procedure)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead related cardiac perforation with or without tamponade</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead impedance out of range, low impedance, potential insulation break</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Other ICD lead related: lead noise or oversensing</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead dislodgement (occuring &gt; 180 days post-implant procedure)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead undersensing or loss of sensing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead inability to defibrillate or pace</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Other ICD lead related: no slack in the lead due to probable dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Other ICD lead related: noise consistent with probable fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Other ICD lead related: tension pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Pocket pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Unable to interrogate device</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Suspected generator failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Premature battery depletion, warranting device replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead dislodgement</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead undersensing or loss of sensing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead oversensing or noise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead loose set screw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity (PEA) arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>LV lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Thrombus attached to ICD lead (unrelated to ICD lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection not due to secondary infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Infection due to secondary infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Loose set screw</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Non-healing pocket dehiscence requiring intervention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Impending erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Pain at insertion site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Pocket erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism (unrelated to ICD lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>Shock coils reversed in header</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ICD lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>ICD lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead dislodgement</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
              <event>
                <sub_title>RA lead oversensing or noise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection not due to secondary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1997"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kelly Mohr</name_or_title>
      <organization>BIOTRONIK, INC</organization>
      <phone>800-547-0394</phone>
      <email>kelly.mohr@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

